| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/27/2006 | WO2005101004A3 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) |
| 04/27/2006 | WO2005100390A3 Bob-1 specific t cells and methods to use |
| 04/27/2006 | WO2005087792A3 Materials and methods relating to the treatment of glioblastomas |
| 04/27/2006 | WO2005028492A8 CRYSTALLINE COMPOUND OF 4'-DEMETHYL-4'-PHOSPHATE-2',3'-BISPENTAFLUOROPHENOXYACETYL-4',6'-ETHYLIDENE-β-D-EPIPODOPHYLLOTOXIN GLUCOSIDE EITHER IN ITS FREE FORM OR SOLVATED WITH ETHANOL |
| 04/27/2006 | US20060089674 Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| 04/27/2006 | US20060089410 Combination of chemotherapeutic drugs for increasing antitumor activity |
| 04/27/2006 | US20060089401 Kinase inhibitors |
| 04/27/2006 | US20060089393 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 04/27/2006 | US20060089379 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 04/27/2006 | US20060089345 Indole derivatives, method for preparating same and pharmaceutical compositions containing same |
| 04/27/2006 | US20060089344 E.g., 2-(Methylamino)-2-oxoethyl 3-[1-(1-isoquinolyl)-4-piperidyl]propylcarbamate hydrochloride and 3{2-[1-(2-quinolyl)-4-piperidyl]-ethyl}-1,3-oxazolidine-2,4-dione; preventing or treating a pathology in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FA; analgesics |
| 04/27/2006 | US20060089341 Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands |
| 04/27/2006 | US20060089336 4-Dedimethylamino tetracycline compounds |
| 04/27/2006 | US20060089334 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 04/27/2006 | US20060089327 Combinations comprising epothilones and anti-metabolites |
| 04/27/2006 | US20060089326 Immunostimulatory nucleic acid molecules |
| 04/27/2006 | US20060089317 Treatment of metastatic breast cancer with anthracyclines, and taxanes |
| 04/27/2006 | US20060089313 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 04/27/2006 | US20060089312 Protease inhibitors |
| 04/27/2006 | US20060089303 Cancer-testis antigens |
| 04/27/2006 | US20060089299 Selective treatment of endothelial somatostatin receptors |
| 04/27/2006 | US20060088915 A G protein-coupled receptor protein for the treatment of digestive diseases |
| 04/27/2006 | US20060088881 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules |
| 04/27/2006 | US20060088880 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 04/27/2006 | US20060088832 Tap-70, a novel marker for epithelial tumors |
| 04/27/2006 | US20060088824 Used in assays to identify PAP-1/WIP-1 interaction inhibitors; West Nile virus (WNV) |
| 04/27/2006 | US20060088561 solidifying agent consists of long chain fatty alcohol; carrier is semi-solid at rest and liquefies upon application of shear forces |
| 04/27/2006 | US20060088545 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therary of diseases associated therewith |
| 04/27/2006 | US20060088540 Antagonists and methods for inhibiting angiogenesis |
| 04/27/2006 | US20060088538 Specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells; diagnosis and therapy |
| 04/27/2006 | US20060088537 Protein involved in cancer |
| 04/27/2006 | US20060088536 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles |
| 04/27/2006 | US20060088532 Lymphatic and blood endothelial cell genes |
| 04/27/2006 | US20060088530 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes |
| 04/27/2006 | US20060088526 Humanized anti-CD3 specific antibodies |
| 04/27/2006 | US20060088520 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 04/27/2006 | US20060088513 Antiallergic composition |
| 04/27/2006 | US20060088511 Cancer therapy sensitizer |
| 04/27/2006 | DE102004050111A1 New active substances (e.g. 1-methyl-DL-tryptophan) are indolamine-2,3-dioxygenase enzyme inhibitors useful for the treatment of curative diseases such as cancer, local immune tolerance and/or suppressions and arteriosclerosis |
| 04/27/2006 | CA2626774A1 Class iii slrp for the treatment of cancer |
| 04/27/2006 | CA2595669A1 Inhibition of tumor growth and metastasis by atf2-derived peptides |
| 04/27/2006 | CA2584747A1 Treatment of osteoarthritis and dosing regimen for arzoxifene |
| 04/27/2006 | CA2584702A1 Nitrobenzindoles and their use in cancer therapy |
| 04/27/2006 | CA2584651A1 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds |
| 04/27/2006 | CA2584368A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| 04/27/2006 | CA2584209A1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 04/27/2006 | CA2584207A1 Antiviral oligonucleotides |
| 04/27/2006 | CA2584170A1 Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases |
| 04/27/2006 | CA2584028A1 Method for treating tumors using anti-osteopontin antibodies |
| 04/27/2006 | CA2583943A1 Novel curcumin analogues and uses thereof |
| 04/27/2006 | CA2583576A1 Chimera (double) decoy |
| 04/27/2006 | CA2583367A1 Cytotoxic formulation for combination therapy |
| 04/27/2006 | CA2583177A1 Compounds for nonsense suppression, and methods for their use |
| 04/27/2006 | CA2582885A1 Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| 04/27/2006 | CA2582163A1 Analogs of 17-hydroxywortmannin as pi3k inhibitors |
| 04/27/2006 | CA2580976A1 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
| 04/27/2006 | CA2580913A1 N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| 04/27/2006 | CA2578300A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 04/27/2006 | CA2574518A1 Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine |
| 04/26/2006 | EP1650309A1 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 04/26/2006 | EP1650221A2 Novel compounds |
| 04/26/2006 | EP1650220A2 Anti-VEGF antibodies |
| 04/26/2006 | EP1650205A1 Cyclohexanecarboxylic acid compound |
| 04/26/2006 | EP1650203A1 Process of preparation of benzimidazol-2-yl quinolinone derivatives |
| 04/26/2006 | EP1650199A1 Sulfonamide derivative having isoxazole ring |
| 04/26/2006 | EP1650195A1 Method of inhibiting production of osteopontin |
| 04/26/2006 | EP1650194A1 Protein kinase inhibitor |
| 04/26/2006 | EP1650188A1 Treatment of tumors with RAR alpha selective retinoid compounds in combination with other anti-tumor agents |
| 04/26/2006 | EP1649881A1 Drug releasing elastic band and method |
| 04/26/2006 | EP1649859A1 Pharmaceutical compositions comprising at least one poorly diffusible anticancer drug and a olidodeoxynucleotide immunestimulant |
| 04/26/2006 | EP1649857A2 New use of glutamate antagonists for the treatment of cancer |
| 04/26/2006 | EP1649852A1 Chromatosis remedies |
| 04/26/2006 | EP1649760A1 Composition containing lactic acid bacterium producing equol |
| 04/26/2006 | EP1649054A1 Method for diagnosing colorectal cancers |
| 04/26/2006 | EP1648938A1 Bcl-2 splicing variants |
| 04/26/2006 | EP1648937A1 Product and composition containing a concholepas concholepas hemocyanin (cch) subunit a, and a method of use thereof |
| 04/26/2006 | EP1648906A1 Organosilicon compounds and their use |
| 04/26/2006 | EP1648905A1 Thienopyridine and furopyridine kinase inhibitors |
| 04/26/2006 | EP1648889A1 Isethionate salt of a selective cdk4 inhibitor |
| 04/26/2006 | EP1648875A1 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| 04/26/2006 | EP1648516A2 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| 04/26/2006 | EP1648513A2 Use of adcc-optimized antibodies for treating weak patients |
| 04/26/2006 | EP1648512A2 Anti-cd19 antibodies |
| 04/26/2006 | EP1648506A1 Method for treating synovial sarcoma |
| 04/26/2006 | EP1648498A1 Microsome vaccine |
| 04/26/2006 | EP1648494A2 Novel anti-angiogenetic agent and its use, in particular in cancer treatment |
| 04/26/2006 | EP1648492A2 A novel antiproliferative factor and methods of use |
| 04/26/2006 | EP1648481A1 Viral vectors |
| 04/26/2006 | EP1648465A1 Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 04/26/2006 | EP1648455A2 Anaplastic lymphoma kinase modulators and methods of use |
| 04/26/2006 | EP1648454A1 Cci-779 lyophilized formulations |
| 04/26/2006 | EP1648449A2 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 04/26/2006 | EP1648437A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 04/26/2006 | EP1648428A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 04/26/2006 | EP1648426A2 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 04/26/2006 | EP1648299A1 Remote detection of substance delivery to cells |
| 04/26/2006 | EP1534708B1 Purine derivatives and their use as antiproliferative agents |
| 04/26/2006 | EP1492524B1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours |
| 04/26/2006 | EP1474521B1 An herpes simplex virus complex |
| 04/26/2006 | EP1465852A4 Synthesis of combretastatin a-2 prodrugs |